Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 4, 2005, Pages 457-461

  De Boer, Nanne K H ^a   Van Nieuwkerk, Carin M J ^a   Pages, M Nieves Aparicio ^b   De Boer, Sybrand Y ^b   Derijks, Luc J J ^c   Mulder, Chris J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

6 thioguanine; Adverse events; Autoimmune hepatitis; Azathioprine; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; MERCAPTOPURINE; MYCOPHENOLIC ACID; TACROLIMUS; TIOGUANINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CASE REPORT; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; ENTERITIS; EVALUATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; AZATHIOPRINE; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREDNISONE; THIOGUANINE;

EID: 16444363709     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200504000-00012     Document Type: Article

References (27)

1. Czaja AJ. Autoimmune hepatitis. Clin Liver Dis 2002; 6 (3):xi-xii.
2. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35:7-13.
3. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333:958-963.
4. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000; 32 (1 suppl):181-197.
5. de Jong D, Derijks LJ, Gilissen LP. Maintenance treatment with 6-thioguanine over one year in azathioprine or 6-mercaptopurine intolerant IBD patients. Gut 2003; 52 (suppl VI):A58.
6. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7:181-189.
7. Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, et al. 6-Thioguanine - efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17:503-508.
8. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98:1058-1063.
9. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125:298-303.
10. Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine- intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15:63-67.
11. Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, et al. Remission maintenance by thioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17:1459-1464.
12. Herrlinger KR, Schwab M, Fellermann K, Stange EF. 6-Thioguanine - buried alive? Gastroenterology 2004; 126:940-941.
13. de Jong D, Mulder CJ, van Sorge AA. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine. Gut 2001; 49:874.
14. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16:876-883.
15. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4:622-627.
16. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43:329-339.
17. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111:1133-1145.
18. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.
19. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14:181-187.
20. Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, et al. Thioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003; 18:401-408.
21. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23:589-599.
22. Tapner MJ, Jones BE, Wu WM, Farrell GC. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol 2004; 40:454-463.
23. Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr 2002; 35:391-398.
24. Gilissen LP, Derijks LJ, Bos LP, Verhoeven HM, Bus PJ, Hooymans PM, et al. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2004; 16:705-710.
25. Read AE, Wiesner RH, LaBrecque DR, Tifft JG, Mullen KD, Sheer RL, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986; 104:651-655.
26. Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986; 90:446-454.
27. Holtmann M, Schreiner O, Kohler H, Denzer U, Neurath M, Galle PR, et al. Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine. Dig Dis Sci 2003; 48:1503-1505.